The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2019 | TEAM conditioning prior to auto-HSCT in lymphoma: replacing the B in BEAM?
Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, discusses the multicenter prospective study (NCT02504190) designed to assess the efficacy and toxicity of the TEAM (thiotepa, etoposide, cytarabine, melphalan) conditioning regimen prior to autologous hematopoietic stem cell transplantation (auto-HSCT) for Hodgkin and non-Hodgkin lymphoma. Prof. Mohty reveals that the TEAM regimen is a safe and valid treatment in auto-HSCT patients with high-risk or relapsed/refractory lymphoma, particularly in patients at intermediate or high-risk of central nervous system relapse. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
